AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Quanterix Corporation
Video analysis: QTRX
All videosNo video analysis for this stock yet. Request one from our team.
News: QTRX
Quanterix Names Dr. Yuri Fesko Chief Medical Officer
Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that accomplished physician executive Dr. Yuri Fesko has b
3,635,411 Shares in Quanterix Corporation $QTRX Bought by BlackRock Inc.
BlackRock Inc. bought a new position in shares of Quanterix Corporation (NASDAQ: QTRX) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 3,635,411 shares of the company's stock, valued at approximately $15,705,000. BlackRock Inc. owned about 7.72% of Quanterix as of its
Quanterix Reshapes Sales Strategy, Targets Q4 FDA Decision for Alzheimer's Blood Test
Quanterix NASDAQ: QTRX CEO Everett Cunningham said the company is repositioning its commercial organization and investing in diagnostics and clinical-trial capabilities following the integration of Akoya Biosciences, while acknowledging continued pressure in academic, government and biopharma markets.
Quanterix Corporation (QTRX) Q2 2026 Earnings Call Transcript
Quanterix Corporation (QTRX) Q2 2026 Earnings Call Transcript
Quanterix Q2 Earnings Call Highlights
Quanterix NASDAQ: QTRX reported second-quarter 2026 revenue of $32.9 million and lowered its full-year outlook after management cited broad-based market softness and commercial execution challenges. The company said revenue came in about $3 million, or 9%, below the guidance it provided in May.
Quanterix Names Jim Gute Chief Commercial Officer
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that seasoned healthcare executive Jim Gute has been appointed Chief Commercial Officer of the company. In this role, he will lead a re-acceleration of growth within the company's commercial operations. “We are thrilled to attract commercial leadership of Jim's caliber to Quanterix, at a pivotal time, ahead of our expansion in diagnostics and with renewed focu.
Quanterix Releases Financial Results for the Second Quarter of 2026
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced financial results for the second quarter ended June 30, 2026. “We made meaningful progress in the second quarter, including strengthening our leadership team and preserving cash better than planned. However, revenue fell short of our expectations, driven by execution challenges and continued market softness. We are taking immediate and significant action to im.
Quanterix To Participate in Canaccord Genuity Capital Markets 46th Annual Growth Conference on August 11-12
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that senior management will participate in the Canaccord Genuity Capital Markets 46th Annual Growth Conference at the Intercontinental Hotel in Boston on August 11-12, 2026. Chief Executive Officer Everett Cunningham will engage in a fireside chat that will be webcast live on 1:00 pm ET on Wednesday, August 12th, during which he will provide an update on the C.
